NeuroPace, Inc. (NPCE) Revenue Growth
NeuroPace, Inc. (NPCE) year-over-year revenue growth rate history. Analyze revenue growth in Excel with MarketXLS.
Revenue Growth Data
| Period | YoY Revenue Growth |
|---|---|
| 2022-12-31 | 0.75% |
| 2023-12-31 | 43.72% |
| 2024-12-31 | 22.14% |
| 2025-12-31 | 25.13% |
How NPCE compares with sector peers
| Symbol | Company | Revenue growth (latest fiscal year) |
|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc. | 20.18% |
| ADMA | ADMA Biologics Inc | 19.63% |
| FLGT | Fulgent Genetics Inc. | 13.83% |
| UNH | UnitedHealth Group Incorporated (DE) | 11.81% |
| MOH | Molina Healthcare Inc | 11.75% |
These are five companies in the same sector as NPCE with a comparable annual revenue growth. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get NeuroPace, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Revenue_Growth("NPCE", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | NPCE | $14.41 | +1.98% | 0.13M |
| 3 | ||||
| 4 | ||||
| 5 |